Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market. The new venture, which the manufacturer says will be a separate business, is tasked with developing and commercialising Boehringer’s own biosimilars. “We believe that biosimilars will become a major part of the biopharmaceutical market and will enable many more patients access to important medicines,” explained Wolfram Carius, member of Boehringer’s board of managing directors.
